Previous 10 | Next 10 |
There has been so much progress in treating cancer in just the past 10 years that it could make your head spin. Researchers have identified new ways to fight cancer -- and new ways to diagnose cancer more effectively, too. Close to $150 billion will likely be spent on cancer drugs this year. Th...
The following slide deck was published by bluebird bio, Inc. in conjunction with this Read more ...
While most stocks delivered great returns in 2019, bluebird bio 's (NASDAQ: BLUE) shares fell 11%. And despite a nice upswing to start off the new year, the stock is close to the level it started 2020 after giving up most of its initial gains. Bluebird reported its fiscal 2019 fourth-quarter...
bluebird bio (NASDAQ: BLUE) announced its fourth-quarter and full-year financial results on Tuesday afternoon. The clinical-stage biotech's stock price fell a bit in after-hours trading as investors reacted to the mixed report. Although the company beat its revenue target, bluebird failed t...
bluebird bio (NASDAQ: BLUE ): Q4 GAAP EPS of -$4.04 misses by $0.25 . Revenue of $9.99M (-48.1% Y/Y) beats by $1.76M . Press Release More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news,
- First conditional approval of ZYNTEGLO TM (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β 0 /β 0 genotype in Europe achieved in 2019; Germany launc...
Let me start out by acknowledging that predicting the stocks in any industry that will deliver the best performance over the next decade is a crapshoot. You can take whatever odds there are against successfully doing so and probably double or triple them when it comes to picking the biotech st...
Biotech stocks can be some of the hottest, best-performing stocks on the market. But they're also some of the riskiest. That's why comparing bluebird bio (NASDAQ: BLUE) , a biotech stock with enormous potential, against the more established healthcare giant Gilead Sciences (NASDAQ: GILD) ...
Bristol-Myers Squibb 's (NYSE: BMY) decision to acquire Celgene in a cash and stock transaction valued at $74 billion wasn't particularly well-received. For instance, one of the company's largest institutional shareholders -- Wellington Management -- came out in opposition of the deal on th...
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9 th Annual SVB Leerink Global Healthcare Conference, Wednesday, February 26, at 2:30 p.m. ET at the Lotte New York Palace, New York, NY ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...